A Leu to Ile but not Leu to Val change at HIV-1 reverse transcriptase codon 74 in the background of K65R mutation leads to an increased processivity of K65R+L74I enzyme and a replication competent virus

Virology Journal

Volumn 8, Issue , 2011, Pages

  Chunduri, Himabindu ^a   Rimland, David ^b   Nurpeisov, Viktoria ^a   Crumpacker, Clyde S ^c   Sharma, Prem L ^a,b  

^a ATLANTA VA MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; ISOLEUCINE; LEUCINE; RNA DIRECTED DNA POLYMERASE; VALINE; GAG PROTEIN; MUTANT PROTEIN; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACID SUBSTITUTION; ANTIBODY PRODUCTION; ARTICLE; CODON; CONTROLLED STUDY; DNA SEQUENCE; ENZYME ACTIVITY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; SEQUENCE ANALYSIS; VIRUS REPLICATION; ANTIVIRAL RESISTANCE; BIOSYNTHESIS; CELL CULTURE; DRUG EFFECT; ENZYMOLOGY; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MONONUCLEAR CELL; PROVIRUS; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1; REPLICATION COMPETENT VIRUSES;

AMINO ACID SUBSTITUTION; CELLS, CULTURED; DRUG RESISTANCE, VIRAL; HIV CORE PROTEIN P24; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MUTANT PROTEINS; PROVIRUSES; VIRUS REPLICATION;

EID: 78651588984     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-33     Document Type: Article

References (45)

1. K65R (Pubitemid 38607538)
2. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. UM Parikh L Bacheler D Koontz JW Mellors, J Virol 2006 80 4971 4977 10.1128/JVI.80.10.4971-4977.2006 16641288
3. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane- guanosine and suppress resistance to 3'-azido-3'-deoxythymidine. HZ Bazmi JL Hammond SC Cavalcanti CK Chu RF Schinazi JW Mellors, Antimicrob. Agents Chemother 2000 44 1783 1788 10.1128/AAC.44.7.1783-1788.2000 10858331 (Pubitemid 30422925)
4. Replication-Dependent 65RK Reversion in human immunodeficiency virus type 1 reverse transcriptase double mutant K65R + L74V. PL Sharma V Nurpeisov K Rapp S Skaggs SFC Amat di RF Schinazi, Virology 2004 321 222 234 10.1016/j.virol.2003.11.013 15051383 (Pubitemid 38406037)
5. Coexistence of the K65R/L74V and/or K65R/T215Y mutations on the same HIV-1 genome. M Henry C Tourres P Colson I Ravaux I Poizot-Martin C Tamalet, J Clin Virol 2006 37 227 230 10.1016/j.jcv.2006.07.001 16931138 (Pubitemid 44548472)
6. The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation. ES Svarovskaia JY Feng NA Margot F Myrick D Goodman JK Ly KL White N Kutty R Wang K Borroto-Esoda MD Miller, J Acquir Immune Defic Syndr 2008 48 428 436 10.1097/QAI.0b013e31817bbe93 18614922
7. Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1 infected patients. M Wirden S Lambert-Niclot AG Marcelin L Schneider H Ait-Mohand C Brunet F Angleraud S Amard C Katlama V Calvez, AIDS 2009 23 95 99 10.1097/QAD.0b013e328319bc91 19050391
8. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. A Adachi HE Gendelman S Koenig T Folks R Willey A Rabson MA Martin, J Virol 1986 59 284 291 3016298 (Pubitemid 16013975)
9. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated -galactosidase gene. J Kimpton M Emerman, J Virol 1992 66 2232 2239 1548759
10. AZT-related mutation Lys70Arg in reverse transcriptase of human immunodeficiency virus type 1 confers decrease in susceptibility to ddATP in in vitro RT inhibition assay. PL Sharma PA Chatis AL Dogon DL Mayers FE McCutchan C Page CS Crumpacker, Virology 1996 223 365 369 10.1006/viro.1996.0488 8806572 (Pubitemid 26319597)
11. Decreased processivity of RT containing a didanosine-selected RT mutation: comparative evaluation of the effect of RT mutations in Leu74Val and Met184Val on viral fitness and RT processivity. PL Sharma CS Crumpacker, J Virol 1999 73 8448 8456 10482597 (Pubitemid 29441708)
12. Comparative processivity of HIV-1 reverse transcriptases containing K65R, L74V, M184V and 65R + 74V mutations. PL Sharma J Nettles A Feldman K Rapp RF Schinazi, Antiviral Res 2009 83 317 323 10.1016/j.antiviral.2009.06.002 19555722
13. Fluorescent dye terminator sequencing methods for quantitative determination of replication fitness of HIV-1 containing the codon 74 and 184 mutations in reverse transcriptase. V Nurpeisov SJ Hurwitz PL Sharma, J Clin Microbiol 2003 41 3306 3311 10.1128/JCM.41.7.3306-3311.2003 12843079 (Pubitemid 36842337)
14. Attenuated replication of HIV-1 with a didanosine-selected reverse transcriptase mutation. PL Sharma CS Crumpacker, J Virol 1997 71 846 8851
15. In vitro synthesis of long DNA products in reactions with HIV-RT and nucleocapsid protein. RM Anthony JJ Destefano, J Mol Biol 2007 365 310 324 10.1016/j.jmb.2006.10.007 17070544 (Pubitemid 44838720)
16. p53 enhances the fidelity of DNA synthesis by human immunodeficiency virus type 1 reverse transcriptase. M Bakhanashvili, Oncogene 2001 20 7635 7644 10.1038/sj.onc.1204956 11753641 (Pubitemid 33111863)
17. Evidence of interactions between the nucleocapsid protein NCp7 and the reverse transcriptase of HIV-1. S Druillennec A Caneparo H de Rocquigny BP Roques, J Biol Chem 1999 274 11283 11288 10.1074/jbc.274.16.11283 10196217
18. Interaction between human immunodeficiency virus type 1 reverse transcriptase and integrase proteins. EA Hehl P Joshi GV Kalpana VR Prasad, J Virol 2004 78 5056 5067 10.1128/JVI.78.10.5056-5067.2004 15113887 (Pubitemid 38581457)
19. Human immunodeficiency virus type 1 nucleocapsid protein (NCp7) directs specific initiation of minus-strand DNA synthesis primed by human tRNA (Lys3) in vitro: studies of viral RNA molecules mutated in regions that flank the primer binding site. X Li Y Quan EJ Arts Z Li BD Preston H de Rocquigny BP Roques JL Darlix L Kleiman MA Parnaik MA Wainberg, J Virol 1996 70 4096 5004
20. Recombination during reverse transcription: an evaluation of the role of the nucleocapsid protein. M Negroni H Buc, J Mol Biol 1999 286 15 31 10.1006/jmbi.1998.2460 9931246 (Pubitemid 29078392)
21. Human immunodeficiency virus type 1 reverse transcriptase: enhancement of activity by interaction with cellular topoisomerase I. H Takahashi M Matsuda A Kojima T Sata T Andoh T Kurata K Nagashima WW Hall, Proc Natl Acad Sci USA 1995 92 5694 5698 10.1073/pnas.92.12.5694 7539924
22. Identifying and characterizing a functional; HIV-1 reverse transcriptase-binding site on integrase. TA Wilkinson K Januszyk ML Phillips SS Tekeste M Zhang JT Miller SF le Grice RT Clubb SA Chow, J Biol Chem 2009 284 7931 7939 10.1074/jbc.M806241200 19150986
23. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. NKT Back M Nijhuis W Keulen CAB Boucher BB Oude Essink ABP van Kuilenburg AH van Gennip B Berkhout, EMBO J 1996 15 4040 4049 8670908 (Pubitemid 26289813)
24. Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1. PL Boyer SH Hughes, Antimicrob Agents Chemother 1995 39 1624 1628 7492119
25. The risks and incidence of K65R and L74V mutations and subsequent virologic responses. L Waters M Nelson S Manalia M Bower T Powels B Gazzard J Stebbing, Clin Infect Dis 2008 46 96 100 10.1086/523001 18171220 (Pubitemid 351263566)
26. Clonal analyses of HIV quasispecies in patients harbouring plasma genotype with K65R mutation associated with thymidine analogue mutations or L74V substitution. M Wirden I Malet A Derache AG Marcelin B Roquebert A Simon M Kirstetter LM Joubert C Katlama V Calvez, AIDS 2005 19 630 632 10.1097/01.aids.0000163942.93563.fd 15802984 (Pubitemid 40543988)
27. Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type1 reverse transcriptase. NK Back B Berkhout, Antimicrob Agents Chemother 1997 41 2484 2491 9371354 (Pubitemid 27467561)
28. A loss of viral replicative capacity correlates with altered DNA polymerization kinetics by the human immunodeficiency virus reverse transcriptase bearing the K65R and L74V dideoxynucleoside resistance substitutions. J Deval JM Navarro B Selmi J Courcambeck J Boretto P Halfon S Garrido-Urbani J Sire B Canard, J Biol Chem 2004 279 25489 25496 10.1074/jbc.M313534200 15044478 (Pubitemid 38756807)
29. Apparent defects in processive DNA synthesis, strand transfer, and primer elongation of Met-184 mutants of HIV-1 reverse transcriptase derive solely from a dNTP utilization defect. L Gao MN Hanson M Balakrishnan PL Boyer BP Roques SH Hughes B Kim RA Bambara, J Biol Chem 2008 283 9196 9205 2008 10.1074/jbc.M710148200 18218634
30. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. KL White NA Margot T Wrin CJ Petropoulos MD Miller LK Naeger, Antimicrob Agents Chemother 2002 46 3437 3446 10.1128/AAC.46.11.3437-3446.2002 12384348 (Pubitemid 35192909)
31. Effects of K65R and K65R/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance. HT Xu JL Martinez-Cajas ML Ntemgwa D Coutsinos FA Frankel BG Brenner MA Wainberg, Retrovirology 2009 6 14 19210791
32. The processivity of DNA synthesis exhibited by drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptases. O Avidan A Hizi, Nucleic Acids Res 1998 26 1713 1717 10.1093/nar/26.7.1713 9512543 (Pubitemid 28291807)
33. A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at position 74 and 75 via the template primer. PL Boyer HQ Gao SH Hughes, Antimicrob Agents Chemother 1998 42 447 452 9527805 (Pubitemid 28114464)
34. Mutagenic study of codons 74 and 215 of the human immunodeficiency virus type 1 reverse transcriptases, which are significant in nucleoside analog resistance. SF Lacey BA Larder, J Virol 1994 68 3421 3424 7512165 (Pubitemid 24129796)
35. Reduced dNTP binding affinity of 3TC-resistant M184I HIV-1 reverse transcriptase variants responsible for viral infection failure in macrophage. VK Jamburuthugoda JM Santos-Velazquez M Skasko DJ Operario V Purohit P Chugh EA Szymanski JE Wedekind RA Bambara B Kim, J Biol Chem 2008 283 9206 9216 10.1074/jbc.M710149200 18218633
36. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase:implications for drug resistance. H Huang R Chopra GL Verdine SC Harrison, Science 1998 282 1669 1675 10.1126/science.282.5394.1669 9831551 (Pubitemid 28549275)
37. Loss of polymerase activity due to Tyr to Phe substitution in the YMDD motif of human immunodeficiency virus type-1 reverse transcriptase is compensated by Met to Val substitution within the same motif. D Harris PN Yadav VN Pandey, Biochemistry 1998 37 9630 9640 10.1021/bi980549z 9657675 (Pubitemid 28319607)
38. Second-site reversion of a human immunodeficiency virus type 1 reverse transcriptase mutant that restores enzyme function and replication capacity. I Olivares V Sanchez-Merino MA Martinez E Domingo C Lopez-Galindez L Menendez-Arias, J. Virol 1999 73 6293 6298 10400720 (Pubitemid 29327805)
39. Diminished efficiency of HIV-1 reverse transcriptase containing the K65R and M184V drug resistance mutations. FA Frankel CF Invernizzi M Oliveira MA Wainberg, AIDS 2007 21 665 675 10.1097/QAD.0b013e3280187505 17413687 (Pubitemid 46568623)
40. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. BA Larder SD Kemp PR Harrigan, Science 1995 269 696 699 10.1126/science.7542804 7542804
41. Antiretroviral drug resistance: mechanisms, pathogenesis, clinical significance. DD Richman, Adv Exp Med Biol 1996 394 383 395 8815703
42. Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J Deval KL White MD Miller NT Parkin J Courcambeck P Halfon B Selmi J Boretto B Canard, J Biol Chem 2004 279 509 516 10.1074/jbc.M308806200 14551187 (Pubitemid 38044852)
43. Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase. UM Parikh S Zelina N Sluis-Cremer JW Mellors, AIDS 2006 21 1405 1414 10.1097/QAD.0b013e3281ac229b (Pubitemid 46988000)
44. HIV-1 subtype B proteases and reverse transcriptases amino acid covariation. SY Rhee TF Liu SP Holmes RW Shafer, PLoS Comput Biol 2007 3 87 10.1371/journal.pcbi.0030087 17500586
45. Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine. ES Svarovskaia NA Margot AS Bae JM Waters D Goodman L Zhong K Borroto-Esoda MD Miller, J Acquir Immune Defic Syndr 2007 46 174 180 10.1097/QAI.0b013e31814258c0 17667333 (Pubitemid 47482612)